Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma

This trial is a single-arm, single-center, open-label clinical trial to evaluate the safety, efficacy, and metabolism kinetics of CT071 in patients with high-risk newly diagnosed multiple myeloma.

Trial Details

NCT ID

NCT06407947

Phase

EARLY_PHASE1

Sponsor

Shanghai Changzheng Hospital

Status

RECRUITING

Cancer Type

Newly Diagnosed Multiple Myeloma

Interventions

Chimeric antigen receptor modified T cells Infusion

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Participants must meet all of the following criteria to be enrolled:
Volunteer to participate in the clinical trial; the participants themselves fully understand and are informed of this study, and sign the informed …
Age ≥ 18 years, male or female;
Participants must have newly diagnosed with multiple myeloma according to International Myeloma Working Group diagnostic criteria 2014 ;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →